Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 2.6% during the fourth quarter, HoldingsChannel reports. The fund owned 322,576 shares of the biotechnology company’s stock after acquiring an additional 8,311 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Astria Therapeutics were worth $2,884,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. New York State Common Retirement Fund lifted its position in shares of Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the last quarter. Quest Partners LLC lifted its holdings in Astria Therapeutics by 180.8% during the 3rd quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,798 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Astria Therapeutics in the 4th quarter worth approximately $107,000. PDT Partners LLC bought a new stake in shares of Astria Therapeutics in the 3rd quarter valued at approximately $140,000. Finally, SG Americas Securities LLC increased its holdings in shares of Astria Therapeutics by 51.3% in the 4th quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 7,218 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Down 0.8 %

ATXS stock opened at $6.06 on Friday. The stock has a market cap of $341.99 million, a PE ratio of -2.90 and a beta of 0.69. The firm’s 50-day simple moving average is $6.84 and its 200 day simple moving average is $9.19. Astria Therapeutics, Inc. has a fifty-two week low of $5.73 and a fifty-two week high of $14.79.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. Equities analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on ATXS. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities initiated coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, March 11th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Astria Therapeutics presently has an average rating of “Buy” and a consensus price target of $26.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.